.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,041,680

« Back to Dashboard

Details for Patent: 7,041,680

Title:(R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same
Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl) isoindolines reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
Inventor(s): Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Apr 10, 2002
Application Number:10/119,486
Claims:1. A pharmaceutical composition comprising a therapeutically effective amount of the (S)-isomer of a compound of the formula: ##STR00007## or an acid addition salt of said isomer, wherein the (S) isomer is substantially free of its (R) isomer, in combination with a pharmaceutically and physiologically suitable carrier.

2. A single unit dosage form of the pharmaceutical composition according to claim 1, wherein the dosage form is a powder, tablet, capsule or an injectable composition.

3. A pharmaceutical composition comprising a therapeutically effective amount of the (R)-isomer of a compound of the formula: ##STR00008## or an acid addition salt of said isomer, wherein the (R) isomer is substantially free of its (S) isomer, in combination with a pharmaceutically and physiologically suitable carrier.

4. A single unit dosage form of the pharmaceutical composition according to claim 3, wherein the dosage form is as a powder, tablet, capsule or an injectable composition.

5. The pharmaceutical composition of claim 1, wherein the (S) isomer has an optical purity of greater than 95%.

6. The pharmaceutical composition of claim 3, wherein the (R) isomer has an optical purity of greater than 95%.

7. The pharmaceutical composition of claim 1, wherein the composition is suitable for parenteral administration.

8. The pharmaceutical composition of claim 7, which is a composition suitable for intravenous administration.

9. The pharmaceutical composition of claim 7, which comprises a sterile injectable solution.

10. The pharmaceutical composition of claim 3, wherein the composition is suitable for parenteral administration.

11. The pharmaceutical composition of claim 10, which is a composition suitable for intravenous administration.

12. The pharmaceutical composition of claim 10, which comprises a sterile injectable solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc